A Phase 2/3 interventional study of PRO 140 and Placebo in HIV, sponsored by CytoDyn, Inc.. Completed at 36 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-03.
Sponsored by CytoDyn, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 2b/3, multi-center, two part study, designed to evaluate the efficacy, safety, and tolerability of PRO 140 in conjunction with existing ART (failing regimen) for one week and Optimized Background Therapy (OBT) for 24 weeks respectively. Study population includes treatment-experienced HIV-infected patients with CCR5-tropic virus who demonstrates evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented genotypic or phenotypic resistance to ART drugs within three drug classes (or within two or more drug classes with limited treatment options).The options may be limited as a result of drug antiviral class cross-resistance or documented treatment intolerance.
PRO 140, in combination with other antiretroviral agents, is indicated for treatment experienced adult HIV-1 patients infected with CCR5-tropic virus. These patients must demonstrate evidence of HIV-1 replication despite ongoing antiretroviral therapy and have documented genotypic or phenotypic resistance to at least one ART drug within three drug classes (or within two or more drug classes with limited treatment option). The options may be limited as a result of drug antiviral class cross-resistance, documented treatment intolerance, documented objective assessments such as renal or hepatic insufficiency (e.g. high creatinine at baseline, limiting treatment options due to potential for toxicity), past adverse reactions such as hypersensitivity reactions or neuropsychiatric issues that could limit use of currently approved drugs.
Study population includes treatment-experienced HIV-infected patients with CCR5-tropic virus who demonstrates evidence of HIV-1 replication despite ongoing antiretroviral therapy with documented genotypic or phenotypic resistance to ART drugs within three drug classes (or within two drug classes with limited treatment option).
Enrollment will be stratified to have HIV-1 virus resistant to ART drugs within three drug classes or within two drug classes with limited treatment option.
The primary objective is to assess the efficacy, clinical safety and tolerability parameters of PRO 140 compared to placebo in reducing HIV-1 viral load during the 1-week double-blind treatment period. The secondary objectives of the trial are to assess the efficacy, clinical safety and tolerability parameters of PRO 140 in combination with Optimized Background Therapy during the 24-week single-arm, open-label treatment period.
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Treatment-experienced -infected patients with documented genotypic or phenotypic resistance to at least one ART drug within three drug classes
OR
Treatment-experienced HIV-infected patients with documented genotypic or phenotypic resistance to at least one ART drug within two drug classes and have limited treatment options. The options may be limited as a result of drug antiretroviral class cross-resistance or documented treatment intolerance.
Laboratory values at Screening of:
Note: Subjects diagnosed with either substance dependence or substance abuse or any history of a concomitant condition (e.g., medical, psychologic, or psychiatric) may be enrolled if in the opinion of site investigator these circumstances would not interfere with the subject's successful completion of the study requirements.
Exclusion Criteria:
Treatment with any of the following:
Oral or parenteral within 30 days prior to the Screening Visit or during the study. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRO140 350mg weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
Drug: PRO 140 · Drug: Optimized Background Regimen
Placebo weekly SC Inj. + existing ART for one week. After one week, all subjects will enter the 24-week single-arm, open-label treatment period. During this period, all subjects will receive PRO 140 SC injection and Optimized Background Therapy.
Drug: Placebo · Drug: Optimized Background Regimen
PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Also known as: PRO140, CCR5 antagonist, Humanized monoclonal antibody to CCR5
Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
Also known as: Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period
The primary efficacy endpoint will be proportion of participants with a 0.5 log10 or greater reduction in HIV-1 RNA viral load from baseline at the end of the one week double-blind treatment period (Part 1).
Time frame: From baseline visit to week 1 visit
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option.
Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group: a. resistance to ART drugs within two drug class with limited treatment option (N = 24). This outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period . The total number of participants in the study ITT population, 52, is further stratified into two subgroups: 1. Participants with resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24) 2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28) This measure includes only the 24 participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Options
Time frame: From baseline visit to week 1 visit
Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Three Drug Classes
Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group: a. Resistance to ART drugs within three drug classes (N = 28) This outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period . The total number of participants in the study ITT population, 52, is further stratified into two subgroups as follows: 1. Participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24) 2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28) This measure includes only the 28 participants with resistance to ART drugs within three drug classes
Time frame: From baseline visit to week 1 visit
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum
The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at the end of the 1-week double-blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded. The change from baseline in HIV-1 RNA levels was to be compared between the two (2) groups using Analysis of covariance (ANCOVA) with the stratification factor (i.e., Resistance to ART drugs at the time of randomization) included in the model.
Time frame: From baseline visit to week 1 visit
Percentage of Participants Achieving HIV-1 RNA < 400 Copies/mL at Week 25 for All Patients and Within Each Stratum
The number and percentages of subjects achieving HIV-1 RNA \< 400 copies/mL at Week 25, from the open label portion of the study, are presented
Time frame: 25 weeks
Percentage and Number of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 25 for All Patients and Within Each Stratum
The number and percentages of subjects achieving HIV-1 RNA \< 50 copies/mL at Week 25 are presented. This is from the 24 week open label portion of the of the trial.
Time frame: 25 weeks
Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at Week 25 for All Patients and Within Each Stratum
The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.
Time frame: 25 weeks
Mean Change From Baseline in CD4 Cell Count at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum
The raw and change from baseline in CD4 cell count at the end of the 1-week double blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.
Time frame: From baseline visit to week 1 visit
Mean Change From Baseline in CD4 Cell Count at Week 25 for All Patients and Within Each Stratum
The raw and change from baseline in CD4 cell count at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.
Time frame: 25 weeks
Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum
The number and percentage of subjects with a ≥ 1log10 or greater reduction in HIV-1 RNA viral load from baseline was to be presented for the two (2) treatment groups. The analysis of change in viral load was done for subjects with ≥ 1.0 log10 reduction in HIV-1 RNA after the first week of treatment. The analysis is presented for the ITT population
Time frame: From baseline visit to week 1 visit
Tolerability of Repeated Subcutaneous Administration of PRO 140 as Assessed by Study Participants (Using Visual Analogue Scale) and by Investigator-evaluation of Injection Site Reactions
Assessments of subject-perceived injection site pain using the Pain Visual Analog Scale (VAS) were performed during each visit to the clinic for a study visit. Beginning at Treatment Visit 2 (T2), subjects were asked to mark the point that best represents the average pain intensity over the past week at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, "no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The subject marks on the line or by pointing to a position on the line the point that they feel represents their perception of their pain state. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks The scale range is 0mm to 100 mm, with 0 mm = No Pain and 100 mm = Pain as bad as it could possibly be. In this measurement, a lower number corresponds to less perceived pain. T# = Visit Week#
Time frame: 25 weeks
Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale
The investigator was to carefully evaluate the comments of each subject and the response to treatment in order to judge the true nature and severity of the AE. The question of the relationship of AEs to study drug should have been determined by the investigator after thorough consideration of all available facts. To assess severity, the investigator was to use the DAIDS AE grading table for adverse events as well as any injection site reactions.
Time frame: 25 weeks
Frequency of Treatment-Emergent Serious Adverse Events
The incidence of serious adverse events (SAEs) by relationship to the study treatment. In total, there were 16 SAEs reported for eight (8) subjects (15.4%, 8/52). Thirteen of the SAEs were determined to be Unrelated, three were determined to be Unlikely Related to study treatment.
Time frame: 25 weeks
Emergence of Dual/Mixed (D/M)- and CXCR4-tropic Virus in Patients Who Had Exclusive CCR5-tropic Virus at Study Entry.
The number of study participants who had exclusive CCR5-tropic virus at study entry and subsequently developed Dual/Mixed (D/M)- and CXCR4-tropic virus at any time during study treatment while receiving PRO 140.
Time frame: 25 weeks
Participants were enrolled from U.S. sites only. The first participant was enrolled on 21 October 2015 and the last subject completed the study on 25 July 2018.
| Milestone | PRO 140 | Placebo |
|---|---|---|
| Started | 25 | 27 |
| Completed | 25 | 26 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Milestone | PRO 140 | Placebo |
|---|---|---|
| Started | 25 | 26 |
| Completed | 25 | 21 |
| Not completed | 0 | 5 |
| Withdrew: Non-medical | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Subject non compliant | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
The primary efficacy endpoint will be proportion of participants with a 0.5 log10 or greater reduction in HIV-1 RNA viral load from baseline at the end of the one week double-blind treatment period (Part 1).
| Proportion of subjects | PRO 140 | Placebo |
|---|---|---|
| With >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline | .64 | .23 |
| Without >= 0.5 LOG10 IN HIV-1 RNA VIRAL Load Change from Baseline | .36 | .77 |
Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group: a. resistance to ART drugs within two drug class with limited treatment option (N = 24). This outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period . The total number of participants in the study ITT population, 52, is further stratified into two subgroups: 1. Participants with resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24) 2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28) This measure includes only the 24 participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Options
| Proportion of participants | PRO 140 | Placebo |
|---|---|---|
| Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option. | .7273 | .2308 |
Proportion of participants with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period, stratified to each group: a. Resistance to ART drugs within three drug classes (N = 28) This outcome measures the proportion of participants that are classified as having a resistance to ART drugs within two drug classes and with limited treatment options with ≥ 0.5 log10 reduction in HIV-1 RNA viral load from baseline at the end of the 1-week double-blind treatment period . The total number of participants in the study ITT population, 52, is further stratified into two subgroups as follows: 1. Participants with Resistance to ART Drugs Within Two Drug Class With Limited Treatment Option (N = 24) 2. Participants with resistance to ART Drugs Within Three Drug Classes (N = 28) This measure includes only the 28 participants with resistance to ART drugs within three drug classes
| Proportion of participants | PRO 140 | Placebo |
|---|---|---|
| Proportion of Participants With ≥ 0.5 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period, Stratified to Each Group: Resistance to ART Drugs Within Three Drug Classes | .5714 | .2308 |
The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at the end of the 1-week double-blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded. The change from baseline in HIV-1 RNA levels was to be compared between the two (2) groups using Analysis of covariance (ANCOVA) with the stratification factor (i.e., Resistance to ART drugs at the time of randomization) included in the model.
| Log10 Copies/mL | PRO 140 | Placebo |
|---|---|---|
| Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum | 0.6 ± 0.45 | 0.1 ± 0.51 |
The number and percentages of subjects achieving HIV-1 RNA \< 400 copies/mL at Week 25, from the open label portion of the study, are presented
| Participants | Part 2 Open Label Portion |
|---|---|
| With HIV-1 RNA < 400 Copies/mL at Week 25 | 37 |
| Without HIV-1 RNA < 400 Copies/mL at Week 25 | 3 |
| Missing | 12 |
The number and percentages of subjects achieving HIV-1 RNA \< 50 copies/mL at Week 25 are presented. This is from the 24 week open label portion of the of the trial.
| Participants | Part 2 Open Label Portion |
|---|---|
| With HIV-1 RNA < 50 Copies/mL at Week 25 | 32 |
| Without HIV-1 RNA < 50 Copies/mL at Week 25 | 8 |
| Missing | 12 |
The raw and change from baseline in HIV-1 RNA levels (log10 copies/mL) at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.
| Log10 copies/mL | Part 2 Open Label Portion |
|---|---|
| Mean Change From Baseline in HIV-1 RNA Levels (log10 Copies/mL) at Week 25 for All Patients and Within Each Stratum | 2.4 ± 1.42 |
The raw and change from baseline in CD4 cell count at the end of the 1-week double blind treatment period was to be summarized by treatment group for the first week during the double-blind treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.
| CD4 Cell Count | PRO 140 | Placebo |
|---|---|---|
| Mean Change From Baseline in CD4 Cell Count at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum | 41.1 ± 154 | 25 ± 131 |
The raw and change from baseline in CD4 cell count at Week 25 was to be summarized for each week during the treatment phase. For change from baseline summaries, subjects with an undefined change from baseline, because of missing data, were to be excluded.
| CD4 Cell Count | Part 2 Open Label Portion |
|---|---|
| Mean Change From Baseline in CD4 Cell Count at Week 25 for All Patients and Within Each Stratum | 85.9 ± 175.2 |
The number and percentage of subjects with a ≥ 1log10 or greater reduction in HIV-1 RNA viral load from baseline was to be presented for the two (2) treatment groups. The analysis of change in viral load was done for subjects with ≥ 1.0 log10 reduction in HIV-1 RNA after the first week of treatment. The analysis is presented for the ITT population
| Proportion of participants | PRO 140 | Placebo |
|---|---|---|
| Proportion of Participants With ≥ 1 log10 Reduction in HIV-1 RNA Viral Load From Baseline at the End of the 1-week Double-blind Treatment Period for All Patients and Within Each Stratum | .2 | .0385 |
Assessments of subject-perceived injection site pain using the Pain Visual Analog Scale (VAS) were performed during each visit to the clinic for a study visit. Beginning at Treatment Visit 2 (T2), subjects were asked to mark the point that best represents the average pain intensity over the past week at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, "no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The subject marks on the line or by pointing to a position on the line the point that they feel represents their perception of their pain state. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks The scale range is 0mm to 100 mm, with 0 mm = No Pain and 100 mm = Pain as bad as it could possibly be. In this measurement, a lower number corresponds to less perceived pain. T# = Visit Week#
| Units on a scale | Part 2 Open Label Portion |
|---|---|
| T2 (Week 2) Left Side Injection Site | 1.3 ± 8.5 |
| T2 (Week 2) Right Side Injection Site | 1.0 ± 7.1 |
| T3 (Week 3) Left Side Injection Site | 0.3 ± 1.5 |
| T3 (Week 3) Right Side Injection Site | 0.2 ± 0.7 |
| T4 (Week 4) Left Side Injection Site | 0.4 ± 1.7 |
| T4 (Week 4) Right Side Injection Site | 0.3 ± 1.1 |
| T5 (Week 5) Left Side Injection Site | .7 ± 4 |
| T5 (Week 5) Right Side Injection Site | .1 ± .6 |
| T6 (Week 6) Left Side Injection Site | .8 ± 4.8 |
| T6 (Week 6) Right Side Injection Site | .3 ± 1.7 |
| T7 (Week 7) Left Side Injection Site | .2 ± .9 |
| T7 (Week 7) Right Side Injection Site | .3 ± 1.7 |
| T8 (Week 8) Left Side Injection Site | .3 ± 1.3 |
| T8 (Week 8) Right Side Injection Site | .4 ± 1.5 |
| T9 (Week 9) Left Side Injection Site | .2 ± .8 |
| T9 (Week 9) Right Side Injection Site | .2 ± .9 |
| T10 (Week 10) Left Side Injection Site | .3 ± 1.1 |
| T10 (Week 10) Right Side Injection Site | .3 ± 1.1 |
| T11 (Week 11) Left Side Injection Site | .3 ± 1.1 |
| T11 (Week 11) Right Side Injection Site | .2 ± 1 |
| T12 (Week 12) Left Side Injection Site | .9 ± 3 |
| T12 (Week 12) Right Side Injection Site | .8 ± 2.7 |
| T13 (Week 13) Left Side Injection Site | .1 ± .9 |
| T13 (Week 13) Right Side Injection Site | .1 ± .9 |
| T14 (Week 14) Left Side Injection Site | .4 ± 1.7 |
| T14 (Week 14) Right Side Injection Site | .4 ± 1.8 |
| T15 (Week 15) Left Side Injection Site | .1 ± .6 |
| T15 (Week 15) Right Side Injection Site | .2 ± .9 |
| T16 (Week 16) Left Side Injection Site | .4 ± 1.6 |
| T16 (Week 16) Right Side Injection Site | .2 ± .8 |
| T17 (Week 17) Left Side Injection Site | .1 ± .4 |
| T17 (Week 17) Right Side Injection Site | .1 ± .4 |
| T18 (Week 18) Left Side Injection Site | .2 ± 1.2 |
| T18 (Week 18) Right Side Injection Site | .3 ± 1.5 |
| T19 (Week 19) Left Side Injection Site | .3 ± 1.3 |
| T19 (Week 19) Right Side Injection Site | .2 ± 1.3 |
| T20 (Week 20) Left Side Injection Site | 1.5 ± 8.9 |
| T20 (Week 20) Right Side Injection Site | 1.1 ± 6 |
| T21 (Week 21) Left Side Injection Site | .8 ± 4.5 |
| T21 (Week 21) Right Side Injection Site | .4 ± 1.8 |
| T22 (Week 22) Left Side Injection Site | .2 ± .9 |
| T22 (Week 22) Right Side Injection Site | .2 ± .8 |
| T23 (Week 23) Left Side Injection Site | .3 ± 1.7 |
| T23 (Week 23) Right Side Injection Site | .2 ± .9 |
| T24 (Week 24) Left Side Injection Site | .2 ± 1.4 |
| T24 (Week 24) Right Side Injection Site | 0 ± .2 |
| T25 (Week 25) Left Side Injection Site | .1 ± .6 |
| T25 (Week 25) Right Side Injection Site | 0 ± .3 |
The investigator was to carefully evaluate the comments of each subject and the response to treatment in order to judge the true nature and severity of the AE. The question of the relationship of AEs to study drug should have been determined by the investigator after thorough consideration of all available facts. To assess severity, the investigator was to use the DAIDS AE grading table for adverse events as well as any injection site reactions.
| Number of Adverse Events | Part 2 Open Label Portion |
|---|---|
| Moderate AEs | 40 |
| Severe AEs | 15 |
The incidence of serious adverse events (SAEs) by relationship to the study treatment. In total, there were 16 SAEs reported for eight (8) subjects (15.4%, 8/52). Thirteen of the SAEs were determined to be Unrelated, three were determined to be Unlikely Related to study treatment.
| Number of Serious Adverse Events | Part 2 Open Label Portion |
|---|---|
| Unrelated | 13 |
| Unlikely Related | 3 |
The number of study participants who had exclusive CCR5-tropic virus at study entry and subsequently developed Dual/Mixed (D/M)- and CXCR4-tropic virus at any time during study treatment while receiving PRO 140.
| Participants | Part 2 Open Label Portion |
|---|---|
| Emergence of Dual/Mixed (D/M)- and CXCR4-tropic Virus in Patients Who Had Exclusive CCR5-tropic Virus at Study Entry. | 2 |
Collected over 25 weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pro 140 Weekly for 1 Week | 0/25 (0%) | 0/25 (0%) | 2/25 (8%) |
| Placebo Weekly for 1 Week | 0/27 (0%) | 0/27 (0%) | 2/27 (7.4%) |
| Part 2 PRO 140 Open Label for 24 Weeks | 0/52 (0%) | 8/52 (15.4%) | 34/52 (65.4%) |
| Event | Pro 140 Weekly for 1 Week | Placebo Weekly for 1 Week | Part 2 PRO 140 Open Label for 24 Weeks |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/25 | 0/27 | 3/52 |
| LymphadenopathyBlood and lymphatic system disorders | 0/25 | 0/27 | 1/52 |
| DiarrhoeaGastrointestinal disorders | 0/25 | 0/27 | 1/52 |
| PancreatitisGastrointestinal disorders | 0/25 | 0/27 | 1/52 |
| Mycobacterium avium complex infectionInfections and infestations | 0/25 | 0/27 | 1/52 |
| Septic shockInfections and infestations | 0/25 | 0/27 | 1/52 |
| DehydrationMetabolism and nutrition disorders | 0/25 | 0/27 | 1/52 |
| MalnutritionMetabolism and nutrition disorders | 0/25 | 0/27 | 1/52 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/25 | 0/27 | 1/52 |
| ConvulsionNervous system disorders | 0/25 | 0/27 | 1/52 |
| Event | Pro 140 Weekly for 1 Week | Placebo Weekly for 1 Week | Part 2 PRO 140 Open Label for 24 Weeks |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/25 | 0/27 | 6/52 |
| Injection site haemorrhageGeneral disorders | 0/25 | 1/27 | 5/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/25 | 0/27 | 5/52 |
| FatigueGeneral disorders | 1/25 | 0/27 | 3/52 |
| Back painMusculoskeletal and connective tissue disorders | 0/25 | 0/27 | 3/52 |
| PneumoniaInfections and infestations | 0/25 | 0/27 | 3/52 |
| Upper respiratory tract infectionInfections and infestations | 0/25 | 0/27 | 3/52 |
| RashSkin and subcutaneous tissue disorders | 0/25 | 0/27 | 3/52 |
| NauseaGastrointestinal disorders | 1/25 | 0/27 | 2/52 |
| Injection site painGeneral disorders | 0/25 | 1/27 | 2/52 |
Intent-to-Treat: The Intent-to-Treat (ITT) population was defined as the set of subjects who were randomized and had received at least one (1) dose of leronlimab (PRO 140) or placebo. This population was to be used as the primary analysis population for the primary and secondary endpoints
| Age, Continuous(years) | PRO 140 | Placebo | Total |
|---|---|---|---|
| Mean | 52.4 ± 8.6 | 52.4 ± 6.7 | 52.4 ± 7.6 |
| Sex: Female, Male(Participants) | PRO 140 | Placebo | Total |
|---|---|---|---|
| Female | 8 | 6 | 14 |
| Male | 17 | 21 | 38 |
| Race (NIH/OMB)(Participants) | PRO 140 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 11 | 13 | 24 |
| White | 14 | 13 | 27 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | PRO 140 | Placebo | Total |
|---|---|---|---|
| United States | 25 | 27 | 52 |
| Time since HIV Diagnosis(years) | PRO 140 | Placebo | Total |
|---|---|---|---|
| Mean | 20.0 ± 9.5 | 20.8 ± 9.4 | 20.4 ± 9.4 |
| Lowest CD4+ Cell Count(Participants) | PRO 140 | Placebo | Total |
|---|---|---|---|
| <200 cells/mm^3 | 10 | 12 | 22 |
| 200-500 cells/mm^3 | 13 | 14 | 27 |
| >500 cells/mm^3 | 2 | 1 | 3 |
| Number of ART Drug Exposure Prior to Enrollment(Number of ART Drugs prior to enrolment) | PRO 140 | Placebo | Total |
|---|---|---|---|
| Mean | 11.8 ± 4.8 | 9.6 ± 4.2 | 10.7 ± 4.6 |
| Number of ART Drug with Documented Resistance(Number of ART drugs with resistance) | PRO 140 | Placebo | Total |
|---|---|---|---|
| Mean | 9.4 ± 5.8 | 8.8 ± 3.3 | 9.1 ± 4.6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Feb 2018, 28 months.
Results were first posted in Nov 2022, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab